虎芪益肾健脾调肝颗粒方合阿德福韦酯治疗慢性乙肝肝纤维化48例

Huqi Yishen Jianpi Tiaogan Granule and adefovir dipivoxil on chronic hepatitis B hepatic fibrosis

目的:观察虎芪益肾健脾调肝颗粒合阿德福韦酯对慢性乙肝肝纤维化的临床疗效。方法:95例患者按随机数字表法分为治疗组48例,给予虎芪益肾健脾调肝颗粒及阿德福韦酯口服,连服48周;对照组47例,给予阿德福韦酯口服,疗程同治疗组。分别于24周、48周结束后,测患者HBV-DNA转阴率,肝功能(ALT、AST),血清肝纤维化指标(HA、IV-C、PcIII、LN)、血清IL-2、IL-6、TGF-β1、TIMP-1、PDGF、TNF-α等因子的浓度及患者门静脉、脾静脉宽度及脾脏厚度,均与治疗前对比,同时观察药物不良反应。结果:治疗组各项指标中血清IL-2浓度及HBV-DNA转阴率明显提高,余各项指标明显下降,与治疗前及对照组相比具有显著差异性,(P<0.05)。结论:虎芪益肾健脾调肝颗粒合阿德福韦酯治疗肝纤维化可以明显提高临床疗效。

Objective：To observe the clinical study of Huqi Yishen Jianpi Tiaogan Granule （HYJTG） and ade‐fovir dipivoxil of liver fibrosis in chronic hepatitis B .Methods ：95 patients were randomLy divided into treatment group in medical order 48 cases ,given the HYJTG and the capsule oral adefovir dipivoxil ,even served 48 weeks ;Control group 47cases ,given adefovir dipivoxil capsules of oral therapy with the treatment group .In 24 weeks and 48 weeks after the end of turn rate measurement in patients with HBV‐DNA ,liver function （ALT ,AST） and serum liver fibrosis indexes （HA ,IV‐C ,PcIII ,LN） ,serum IL‐2 ,IL‐6 ,TGF‐beta 1 and TIMP‐1 ,PDGF ,TNF alpha factor such as concen‐tration and patients with portal vein ,splenic vein width and thickness of spleen ,compared with before treatment and the control group ,at the same time observe the adverse drug reactions .Results ：The concentration of serum IL ‐2 in the treatment group the indicators and HBV DNA overcast rate increased significantly ,each index decreased obviously ,com‐pared with before treatment and control group with significant difference （P ＆lt; 0 .05） .Conclusion：HYJTG and the ade‐fovir dipivoxil treatment of liver fibrosis can significantly improve the clinical curative effect .